Trial Profile
A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs DPV 001 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 07 Nov 2013 Status changed from active, no longer recruiting to completed.
- 05 Nov 2013 Results presented at 15th World Conference for Lung Cancer, according to a UbiVac media release.
- 07 Jan 2013 Planned end date changed from 1 Jul 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.